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The Strategy Group of the UKCCCR held a workshop on 18
November, 1999 to consider the issue of ‘Clinical endpoints in
trials of biological agents’. The organizers of the workshop were
Professor Barry Hancock (Chairman, UKCCCR Renal Cancer
Group) and Dr Peter Twentyman (Executive Secretary,
UKCCCR). The workshop was Chaired by Professor Sir William
Asscher (Chairman, UKCCCR) and was attended by representa-
tives of the Cancer Research Campaign (CRC), Imperial Cancer
Research Fund (ICRF), Leukaemia Research Fund (LRF) and
Medical Research Council (MRC), together with a number of
invited speakers and rapporteurs.
In his introductory remarks, the Chairman pointed out that many
new types of agent of interest to cancer therapists could not be
assessed by the same criteria as conventional cytotoxics. This
presents a variety of problems for pharmaceutical companies, clin-
icians and regulatory agencies in designing appropriate trials and
establishing valid endpoints. In doing so, the ultimate goal of
patient benefit must always be the guiding principle.
BACKGROUND TO THE TOPIC
Professor Barry Hancock (University of Sheffield) illustrated
some of the problems by referring to the Aim High trial of alpha
interferon as adjuvant treatment for high risk melanoma. There are
many different types of interferons (both natural and synthetic)
and the dose levels being investigated are clearly superphysio-
logical. Although such agents are most likely to work in the
adjuvant setting, traditional, early-stage clinical testing relies on
the use of patients with ‘end-stage’ tumours. Dose-response and
dose-toxicity relationships may be complicated and the use of
pharmacokinetic data may not be possible or helpful. Problems
such as these would be more specifically highlighted in the
presentations to follow.
DELIVERY, PHARMACOKINETICS,
PHARMACODYNAMICS OF BIOLOGICAL
AGENTS — GENERAL ISSUES
Professor Jim Carmichael (University of Nottingham) outlined the
standard progression for cytotoxics through phase I®II®III often
including pharmacokinetic and pharmacodynamic analysis.
However, with newer types of agents, very low doses were often
used, and both tumour response and toxicity were liable to be
unpredictable. In phase I, it would be difficult to design a schedule
of administration, the toxicity profile may be very unusual and it
may be hard to define ‘evidence of effect’. Some biological agents
may be best administered with prolonged low-dose exposure, may
have bell-shaped dose-response curves and may have an indirect
anti-tumour effect. For agents with specific gene targets it may be
possible to incorporate measurements of gene expression into
phase I and II but the question of tissue-specificity may be
problematic. It may be particularly difficult to agree on what
constitutes sufficient evidence to justify progression to phase III
development.
Dr Julie Sylvester (Drug Development Office, Cancer Research
Campaign) discussed whether the general development strategy
for biological agents should be the same as that for cytotoxics. She
felt that pharmacodynamic endpoints could be particularly useful
for biologicals. In trials of such agents, any novel approaches,
including the use of surrogate endpoints would require careful
validation. Issues raised by GMP would also need to be borne in
mind.
In the discussion, there was much interest in the desirability of
measuring interaction between an agent and its intended target
rather than an overemphasis on pharmacokinetics. A number of
possibilities were presented by the neoadjuvant situation where
tumour tissue could be available at surgery following drug admin-
istration. Pharmacokinetic measurements were usually only made
of plasma concentration whereas the drug concentration in the
tumour was the most relevant determinant of efficacy. Professor
Alaisdair Breckenridge (Chairman, Committee on Safety of
Medicines) emphasized that drug regulation follows science and
that applicants must decide whether pharmacokinetic data would
strengthen any particular case.
CYTOKINES
Dr Tim Eisen (University College London) referred to cytokines
as ‘soluble proteins which act as messengers between cells across
the extracellular environment’. Current examples include inter-
ferons, interleukins, tumour necrosis factor and colony stimulating
factors. They are characterized by pleiotropy, redundancy, and
activity in a wide range of tissues. In cancer therapy they may be
used alone, or in combination with cytotoxics or other cytokines.
In terms of response markers, it is necessary to determine what
type of sample should be taken from what site and how it should
be processed. A variety of downstream events could potentially 
be examined from initial effects on kinase activity to clinical
phenomena such as disrupted blood flow and cellular apoptosis. In
clinical trials it is important to remember that the most effective
dose may not be the highest dose and that delayed responses may
occur. Unusual side-effects such as vascular leak and delayed
auto-immune disease may occur.
Professor Nick Thatcher (University of Manchester) was partic-
ularly interested in cytokines as ‘supportive agents’ for reduction
in toxicity of chemotherapy. Endpoints such as ‘days spent in
hospital’ become relevant in such a situation. Cytokines such as
interferons and interleukins are interesting because they have
some activity in tumour types resistant to conventional
chemotherapy. However, the high cost of such agents dictates that
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health economic analysis will be an essential element of their
clinical development. Clearly, in carrying out such analysis, it 
is important that the right tumour type is studied.
The discussion focused largely on issues relating to combined
use of cytokines and cytotoxics. Evidence that each element of
such combinations contributes to overall efficiency is often
lacking. The presence of vascular leak syndrome at the time of
cytotoxic administration could be a major hazard. There was also 
a problem, where cytokines may produce a delayed tumour
response, in that administration may be stopped early on the
grounds of early progression.
VACCINES
Dr Lindy Durrant (University of Nottingham) presented an
analysis of tumour vaccines and their mode of action. Clearly if
vaccine toxicity is related to expression of a specific antigen then
knowledge of the distribution of the antigen on normal tissue is an
essential prerequisite. For example, an anti-melanoma vaccine
may produce vitiligo by action on melanin-containing normal
cells. Tumour tissue can ‘switch off’ both naive and memory T
cells and therefore it is better to treat minimal residual disease and
immunize aggressively. Phase I trials of vaccines have usually
started in advanced disease and progressed to minimal residual
disease with schedules/doses being modified to optimize the
immune response. Immune monitoring may be carried out on
blood samples using a variety of assays or on tumour samples by
determination of immune infiltrate. As an example, Dr Durrant
quoted their own trial of 105AD7 in colorectal cancer in which
patients were immunized prior to operation and boosted post-oper-
atively. Presence of lymphocyte infiltration (CD4, CD8, CD56 and
CD68) together with tumour cell apoptosis had been measured in
the operative specimen. In all clinical trials of cancer vaccines,
measurement of immune response should be regarded as a vital
endpoint.
Professor Angus Dalgleish (St. George’s Hospital, London)
highlighted a variety of approaches which has been taken in
studies which he had carried out. He emphasized that the genetic
instability of tumour cells and the presence of heterogeneous
clones within tumours presented problems with respect to use of
strategies based on single antigens. He showed clinical data for
response of melanoma to the ‘Morton vaccine’ based on multiple
cell lines, and targeting multiple antigens/epitopes. There had been
good correlation between the (DCDC) and disease-free survival in
patients receiving the vaccine.
In discussion, there was much interest in the need to obtain
information on immune effects occurring at the tumour site.
Professor Thatcher thought that it should be relatively straightfor-
ward to administer a vaccine to patients with progressive disease
and subsequently biopsy responding (and non-responding) metas-
tases. It was felt that the problem of tumour heterogeneity may
hinder interpretation. However, in general, responding nodules
following vaccine therapy are generally seen to have a large
lymphocyte infiltrate. It was not considered possible to judge
which patients were likely to have a good immune response and
this did not depend solely upon bulk of disease. The group consid-
ered whether a phase I study in the neoadjuvant setting would
allow comprehensive study of tumour effects in the resection spec-
imen. However, it was agreed that good vaccines which produced
a delayed effect may be lost via this route. Although measurement
of apoptosis in tumour specimens was a potentially useful
endpoint, the timing of measurements was a difficult and
potentially misleading issue.
GENERAL DISCUSSION
At the end of the morning session there was a General Discussion.
Professor Carmichael was interested in knowing, for various types
of agents, what information, at the end of the Phase I stage, would
incline investigators to proceed to Phase III. Professor
Breckenridge made the point that the Committee on Safety of
Medicines now deals with oncology products in a similar manner
to other drugs, and similar types of evidence would be required.
Professor Dalgleish agreed that it would be unfair to present data
only from ‘responding patients’ and that biological response
should be assessed on an ‘intention to treat’ basis unless there had
been a prior, marker-defined, group in which differential results
had occurred. Concern was expressed however that a potentially
useful agent, very effective in a subgroup of patients may be lost
when decisions are based on results for the whole population.
There was major concern expressed that the important effects of a
novel agent may be missed if Phase II trials were carried out using
an inappropriate schedule. Data to address this concern are not
generally available and it would be difficult to obtain academic
funding for (e.g.) detailed comparisons of schedules.
ANTIBODY-DIRECTED THERAPY
The use of antibody-directed therapy was addressed by Professor
Richard Begent (Royal Free Hospital, London). He began by
outlining the scientific basis of ADEPT (antibody directed enzyme
prodrug therapy) and pointed out the need to determine that each
component of the system was operative. This would include
measurement of enzyme activity in tumour and blood in order that
the prodrug can be administered when the enzyme ratio is very
high. If necessary, methods may be used to clear artificially the
enzyme from the circulation. The relative concentrations of
prodrug versus drug in the plasma can then be ascertained and
various assays used to detect drug-induced lesions in the tumour
cells. Heterogeneity of lesion induction through the tumour may
possibly be demonstrated by immunohistochemistry. Using this
type of approach a number of responses have been seen in Phase I
studies. Progress beyond this will depend upon optimization of
parameters in the compartmental model using numeric values
from clinical experience. This could include: (a) affinity/antigen
and antibody concentrations, (b) flow through tumour extra-
vascular space, (c) elimination of target molecule from tumour,
(d) construction of more stable molecule with improved
tumour/normal tissue ratio.
Professor Terry Hamblin (University of Southampton) believed
that the optimal approach in such studies should rely upon a rela-
tively small number of patients who are very intensively investi-
gated. Novel approaches to Phase I/II testing are likely to be
required in situations where increased dose may not lead to
increased toxicity. Phase I testing often occurs in patients with a
high tumour load and this may act as a ‘sump’ for antibody
resulting in a very high MTD. However, more problematic cross-
reactivity may occur in patients with lower tumour loads. Hence,
choosing the ‘correct dose’ for Phase II may be difficult.
In discussion it was pointed out that, whereas the administered
dose for conventional cytotoxics was likely to be determined 
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would prevail for antibodies. There were mixed views on whether
investigations of therapeutic efficacy should concentrate on
specific cellular targets or more general cellular effects. Not all
effects of antibody-directed therapies would necessarily occur via
interaction with target antigen. The question of when was the
appropriate time to leave a succession of Phase I studies and
proceed to Phase II/III was difficult.
ANTIANGIOGENIC AGENTS
Dr Trivadi Ganesan (University of Oxford) discussed agents
which acted as inhibitors of neoangiogenesis, an essential element
of tumour growth. Such agents could act via a variety of pathways
and include, (a) drugs which inhibit matrix breakdown, (b) drugs
which directly inhibit endothelial cell activity, (c) drugs which
inhibit activators of angiogenesis, (d) drugs that inhibit endothelial
specific integrin/survival signalling, (e) drugs with nonspecific
mechanisms. Conventional criteria for MTD were often not appro-
priate in clinical trials of such agents and surrogate biological
endpoints may be more useful. These could include, (a) target
specific assays, (b) vascular markers, (c) conventional tumour
markers, (d) PET scans, (e) indirect evidence of tumour effects.
Specific problems with antiangiogenic agents include their inef-
fectiveness in bulky disease and the difficulty of combining them
with other modalities in an overall plan of cancer management.
Side effect profiles may be very unusual as essential physiological
functions may be affected.
Professor Ian Hart (St. Thomas’ Hospital, London) believed that
targeting angiogenesis had a number of clear theoretical advan-
tages. Firstly, as normal cells were the target, development of
cellular resistance was unlikely to occur. There was a potential
amplification effect in that destruction of a small number of
endothelial cells may be expected to eliminate large numbers of
tumour cells. Furthermore, the general approach was applicable to
all types of solid tumours – irrespective of their tissue of origin or
histological type. However, there were, in fact, few data available
to support any of these contentions. A very large number of poten-
tially antiangiogenic agents are available but there are few indica-
tors of how they should be prioritized for clinical testing. The
relevance of various laboratory assays remains unclear and anti-
tumour testing in animals has frequently employed model systems
with fundamental differences from human tumours. Professor Hart
believed that the biology is still poorly understood and this makes
it difficult to know when and how clinical trials should proceed.
Current trials have shown disappointing efficacy despite
promising preclinical data.
In discussion, the need for fairly pragmatic trials was empha-
sized. Approaches could include combination with conventional
chemotherapy and in the ‘minimal residual disease’ situation post
surgery. It was agreed that some clinical trials had apparently
shown effects greater than could be predicted from a purely cyto-
static effect following inhibition of neo angiogenesis. Such results
raised questions regarding the mechanism of action of such agents.
REGULATORY AND LICENSING ISSUES
Professor David Linch (University College, London) discussed
how regulatory/licensing issues could impact upon the develop-
ment of agents and the design of clinical trials. In the case of
the use of CSFs as supportive agents, primary endpoints such
as ‘febrile neutropenia’ and ‘microbiologically documented
infections during neutropenia’ had been used after discussion with
the regulatory authorities. These endpoints are largely spurious,
however, and often fail to reflect the duration of a septic episode.
Pharmaco-economic data such as ‘time in hospital’ might be more
clinically relevant but it is a ‘soft’ end-point not favoured by regu-
latory authorities. It is also clear that the regulatory authorities
demand differing endpoints at different stages of a disease. In
lymphoma, at presentation, for example, survival data from
randomized trials is required but in relapsed disease, response data
may be sufficient for licensing. In the USA redefinition of the
‘Phase III trial’ has allowed the use of historical cohorts. Finally, it
must be noted that there is a long tradition in oncology of using
agents for non-licensed indications and the major use for some
cytotoxic agents has been outside of these indications.
Professor Alaisdair Breckenridge (Chairman, Committee on
Safety of Medicines) drew parallels between licensing of anti-
cancer drugs and other types of agents. These have recently
become more similar as cancer agents have moved on from
general cytotoxics to drugs with specific targets. Licensing
depends upon assessment of efficacy and risk/benefit analysis. He
believed there to be good arguments for ‘early licensing’ of cancer
drugs and this would be discussed at a forthcoming CPMO confer-
ence. Surrogate markers were becoming widely used as endpoints
but this was only valid where a clear correlation with clinical
endpoints has been previously established. Use of historical
controls was not automatically unacceptable but should be viewed
with extreme caution. In general, regulatory criteria follow science
and not vice versa!
The use of ‘time to progression’ as a tumour response endpoint
was discussed, particularly in respect of drug licensing. The cancer
experts on the CSM were believed to be not unhappy with the
concept provided that it was properly defined. It was agreed that
‘time to progression’ would not, on its own, be a sufficient basis
for licensing. The question of early versus late licensing is always
difficult but there is, at least, in cancer not the problem of drug use
off-indication by GPs. It was agreed that a common misconception
is that licensing is, in some way, a ‘recommendation for use’.
Increasingly the question of ‘cost-effectiveness’ for cancer drugs
arises and it is this precise issue which will be addressed by the
National Institute for Clinical Excellence. It was pointed out that
companies are often granted a ‘conditional registration’ for the
duration of an ongoing phase III trial.
ETHICS AND FUNDING ISSUES
Dr Brian Scott (Chairman, Trent MREC) emphasized that the
scientific validity of the endpoints used would feature amongst the
issues that an ethics committee would consider in deciding
approval for a clinical trial. This may be more relevant than the
basic aims and design of a trial which, coming from bodies such 
as the MRC, would be expected to be acceptable. There was
however, a strong feeling amongst most of those present that it was
inappropriate for ethics committees to judge the scientific merit of
clinical projects other than in respect of ethical issues.
Dr John Toy (ICRF) pointed out the patients frequently entered
trials when they are at their most vulnerable because they are often
at a stage of their illness when all other treatments have failed.
Explanation of surrogate endpoints at this time, in such a way that
their fully informed consent is validly obtained, may be difficult.
One example would be patients being asked to enter neo-adjuvant
studies when surgery is to be delayed in the placebo arm, in orderUKCCCR Strategy Group Workshop 297
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that its timing matches that in the active biological therapeutic
arm. Another difficulty is obtaining fully informed consent for the
later and presently unknown analyses of tissue sample donations
which are to be stored. A study has shown that the patients who are
prepared to enter into randomized trials are increased in numbers
when a fuller explanation is given to them about the concept of
randomization. Another study, however, has shown that although
doctors are willing to enter patients into studies, difficulties of
time and energy required to identify eligible patients and to obtain
their consent results in fewer than 50% of eligible patients being
entered into trials. An ethical role must be allowed for non-
medically qualified clinical research staff to help with these
activities.
Funding issues predominantly concern the adequacy of
providing a trials infrastructure, registries and databases within the
NHS. These are topics which have recently been identified by
NHS R&D Priorities Working Group as of highest priorities.
FINAL DISCUSSION
The final discussion highlighted a number of points which had not
been mentioned previously. Dr Matt Seymour (Leeds) felt that
even small, early phase, trials could benefit from the use of
randomization rather than historical controls. However, the prob-
lems of acceptability to patients of a ‘no active treatment’ arm
should not be underestimated. With respect to a phase II trial, if
this is intended as a preliminary to a large phase III, then random-
ization is important. If, however, the phase II is expected to further
early development, then randomization is less essential. Finally,
Professor M Dowsett (Institute of Cancer Research) pointed out
that a molecular biologist may often set up an assay without
knowledge of the degree of variability which will be found in clin-
ical samples. Optional use of surrogate endpoints will require good
information regarding such variability.